Latest Articles
Non-invasive blood tests for earlier diagnosis and treatment of endometriosis.
Endometriosis is a chronic condition characterized by the presence of endometrial-like tissue outside the uterus, leading to symptoms such as dysmenorrhea and chronic pain. It affects approximately 2-10 % of …
Published: March 17, 2025, midnight
Groundbreaking Cancer Study: Nivolumab Delivers Remarkable Results for Endometrial Cancer Patients - Elblog.pl
Groundbreaking Cancer Study: Nivolumab Delivers Remarkable Results for Endometrial Cancer Patients Elblog.pl
Published: March 16, 2025, 8:29 p.m.
Add-On Metformin Promising in ER-Positive Endometrial Cancer - Medpage Today
Add-On Metformin Promising in ER-Positive Endometrial Cancer Medpage Today
Published: March 16, 2025, 7:53 p.m.
Metformin Plus IUD Well-Tolerated in EIN/Endometrial Cancer - Cancer Network
Metformin Plus IUD Well-Tolerated in EIN/Endometrial Cancer Cancer Network
Published: March 16, 2025, 7:52 p.m.
Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer - OncLive
Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer OncLive
Published: March 16, 2025, 7:29 p.m.
Hormonal regulation of CFTR and ENAC expression in healthy endometrial... - ResearchGate
Hormonal regulation of CFTR and ENAC expression in healthy endometrial... ResearchGate
Published: March 16, 2025, 5:09 a.m.
Endometrial Cancer Combo Treatment Shows Promise - Mirage News
Endometrial Cancer Combo Treatment Shows Promise Mirage News
Published: March 15, 2025, 11:08 p.m.
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer - OncLive
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer OncLive
Published: March 15, 2025, 4:52 p.m.
Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer - OncLive
Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer OncLive
Published: March 15, 2025, 3:35 p.m.
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer - OncLive
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer OncLive
Published: March 15, 2025, 3:27 p.m.
Link copied to clipboard!